E. (Eric) van Gorp

Prof. dr. Eric C.M. van Gorp is an internist/infectiologist/virologist at the Erasmus MC, heading the clinical working group of Emerging Viral infections [EVI] in the Department of Viroscience.

The EVI group is involved in research in the field of Emerging [outbreak] viruses like Dengue, Ebola, Zika and COVID-19. Vaccine effectiveness studies [multicenter] in risk groups and optimizing vaccination implementation strategies is a second field of expertise.

His field of interest is the social and scientific impact of infectious diseases. He is founder of the Cirion foundation [www.cirion.net], initiating and facilitating initiatives and projects to promote prevention of infectious diseases. One of the initiatives is the EU supported international education and prevention project Viruskenner for scholars [www.viruskenner.nl].

The research line, with several PhD’s, he is supervising is focusing on the emerging viral infections, with an extensive (inter)national network in the Netherlands, the Caribbean, Surinam, Brazil , South Africa, and Indonesia.

He is supervisor of the Vaccination outpatient clinic/Travel clinic and the Clinical trial unit from the Viroscience department on which fase I and II vaccination studies are conducted [e.g. Horizon 2020, CEPI, ZonMW].

Clinical aspects of exotic viruses

Prof. dr. Eric C.M. van Gorp studied medicine at the University of Amsterdam. In 2001 he finished his thesis entitled: "Studies on the pathophysiology of dengue haemorrhagic fever and dengue shock syndrome", granted by the Royal Netherlands Academy of Arts and Sciences (KNAW).

Selection of publications

• Exotic viral hepatitis: A review on epidemiology, pathogenesis, and treatment.
  van Leeuwen LPM, de Jong W, Doornekamp L, van Gorp ECM, Wismans PJ, Goeijenbier M. J Hepatol. 2022 Nov;77(5):1431-1443. doi: 10.1016/j.jhep.2022.06.031. Epub 2022 Jul 9. PMID: 358172222.


• Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity
  Van Leeuwen LPM et al. J Allergy Clin Immunol. 2022 Jun;149(6):1949-1957. doi: 10.1016/j.jaci.2022.04.002. Epub 2022 Apr 11.PMID: 35421449


• The possible role of cross-reactive dengue virus antibodies in Zika virus pathogenesis.
  Langerak T, Mumtaz N, Tolk VI, van Gorp ECM, Martina BE, Rockx B, Koopmans MPG.PLoS Pathog. 2019 Apr 18;15(4):e1007640. doi: 10.1371/journal.ppat.1007640. eCollection 2019 Apr.PMID: 30998804


• Management of patients on antithrombotic therapy with severe infections: a joint clinical consensus statement of the ESC Working Group on Thrombosis, the ESC Working Group on Atherosclerosis and Vascular Biology, and the International Society on Thrombosis and Haemostasis
  Gigante B, Levy JH, van Gorp E, Bartoloni A, Bochaton-Piallat ML, Bäck M, Ten Cate H, Christersson C, Ferreiro JL, Geisler T, Lutgens E, Schulman S, Storey RF, Thachil J, Vilahur G, Liaw PC, Rocca B.Eur Heart J. 2023 Aug 22;44(32):3040-3058. doi: 10.1093/eurheartj/ehad388.PMID: 37439553


• The Potential Role of School Citizen Science Programs in Infectious Disease Surveillance: A Critical Review.
  Abourashed A, Doornekamp L, Escartin S, Koenraadt CJM, Schrama M, Wagener M, Bartumeus F, van Gorp ECM. Int J Environ Res Public Health. 2021 Jun 30;18(13):7019. doi: 10.3390/ijerph18137019.PMID: 34209178 Free PMC article. Review.


• Zika Virus Infection and Guillain-Barré Syndrome in Three Patients from Suriname.
  Langerak T, Yang H, Baptista M, Doornekamp L, Kerkman T, Codrington J, Roosblad J, Vreden SG, De Bruin E, Mögling R, Jacobs BC, Pas SD, GeurtsvanKessel CH, Reusken CB, Koopmans MP, Van Gorp EC, Alberga H. Front Neurol. 2016 Dec 22;7:233. doi: 10.3389/fneur.2016.00233. eCollection 2016.


• Longitudinal follow-up of Zika virus RNA in semen of a traveller returning from Barbados to the Netherlands with Zika virus disease. March 2016
  Reusken C, Pas S, Geurts-van Kessel C, Mögling R, van Kampen J, Langerak T, Koopmans M, van der Eijk A, van Gorp E. Euro Surveill. 2016 Jun 9;21(23). doi: 10.2807/1560-7917.ES.2016.21.23.30251. Erratum in: Euro Surveill. 2016 Jun 16;21(24):. PMID:


• Procalcitonin-guided therapy for the initiation of antibiotics in the ED: a systematic review.
  van der Does Y, Rood PP, Haagsma JA, Patka P, van Gorp EC, Limper M. Am J Emerg Med. 2016 Jul;34(7):1286-93. doi: 10.1016/j.ajem.2016.03.065. Epub 2016 Apr 3. Review.


• Higher diagnostic accuracy and cost-effectiveness using procalcitonin in the treatment of emergency medicine patients with fever
  (The HiTEMP study): a multicenter randomized study. van der Does Y, Limper M, Schuit SC, Poley MJ, van Rosmalen J, Ramakers C, Patka P, van Gorp EC, Rood PP. BMC Emerg Med. 2016 Apr 6;16:17. doi: 10.1186/s12873-016-0081-6.


• TRAIL and IP-10 as biomarkers of viral infections in the emergency department.
  van der Does Y, Tjikhoeri A, Ramakers C, Rood PPM, van Gorp ECM, Limper M. J Infect. 2016 Jun;72(6):761-763. doi: 10.1016/j.jinf.2016.03.004. Epub 2016 Mar 18. No abstract available.


• Comparison of the PRNT and an immune fluorescence assay in yellow fever vaccinees receiving immunosuppressive medication.
  Wieten RW1, Jonker EF2, Pieren DK3, Hodiamont CJ4, van Thiel PP5, van Gorp EC6, de Visser AW2, Grobusch MP5, Visser LG2, Goorhuis A5.


• Factors associated with presenting late or with advanced HIV disease in the Netherlands, 1996-2014: results from a national observational cohort. 
  Op de Coul EL1, van Sighem A2, Brinkman K3, van Benthem BH1, van der Ende ME4, Geerlings S5, Reiss P2; ATHENA

He is visiting professor at the University of Airlanga in Surabaya, Indonesia. He is a member of the advisory board emerging infections Caribbean. His field of interest is the social and scientific impact of infectious diseases; epidemiology, clinical management and pathophysiology. He is founder of the Cirion foundation [www.cirion.net], initiating and facilitating initiatives and projects to promote prevention of infectious diseases.